tg-003 and Cardiovascular-Diseases

tg-003 has been researched along with Cardiovascular-Diseases* in 1 studies

Reviews

1 review(s) available for tg-003 and Cardiovascular-Diseases

ArticleYear
Recent advances in the development of active hybrid molecules in the treatment of cardiovascular diseases.
    Bioorganic & medicinal chemistry, 2022, 05-15, Volume: 62

    Multifactorial nature of the underlying pathophysiology of chronic disorders hinders in the effective treatment and management of many complex diseases. The conventional targeted therapies have limited applications due to highly complicated disease etiology. Cardiovascular diseases (CVDs) are the group of disorders of the heart and blood vessels. Currently, there is limited knowledge on the underlying cellular and molecular mechanisms of many of the CVDs due to their complex pathophysiology and co-morbidities. Their management with conventional medications results in failure due to adverse drug reactions and clinical specificity of solo-targeting drug therapy. Therefore, it is critical to introduce an alternative strategy to treat multi-factorial diseases. In the past few years, discovery and use of multi-targeted drug therapy with hybrid molecules have shown promising results with minimal side effects, and thus considered a most effective approach. In this review article, prominent hybrid molecules combining with different active moieties are reported to synergistically and simultaneously block different pathways involved in CVDs. Here, we provide a critical evaluation and discussion on their pharmacology with mechanistic insights and the structure activity relationship. The timely information provided in this article reveals the recent trends of molecular hybridization to the scientific community interested in CVDs and help them in designing the next generation of multi-targeting drug therapeutics.

    Topics: Cardiovascular Diseases; Drug Delivery Systems; Humans; Molecular Targeted Therapy; Structure-Activity Relationship

2022